165 related articles for article (PubMed ID: 37478179)
1. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.
Li M; Oliveira Passos D; Shan Z; Smith SJ; Sun Q; Biswas A; Choudhuri I; Strutzenberg TS; Haldane A; Deng N; Li Z; Zhao XZ; Briganti L; Kvaratskhelia M; Burke TR; Levy RM; Hughes SH; Craigie R; Lyumkis D
Sci Adv; 2023 Jul; 9(29):eadg5953. PubMed ID: 37478179
[TBL] [Abstract][Full Text] [Related]
2. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
3. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
4. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
[TBL] [Abstract][Full Text] [Related]
5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
6. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
Engelman AN; Cherepanov P
FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
9. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
[TBL] [Abstract][Full Text] [Related]
11. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
[TBL] [Abstract][Full Text] [Related]
12. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
[TBL] [Abstract][Full Text] [Related]
13. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
14. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
18. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
20. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
